Emergence of azole drug resistance in candida species from HIV-infected patients receivingprolonged fluconazole therapy for oral candidosis

Journal of Antimicrobial Chemotherapy

Volumn 35, Issue 1, 1995, Pages 103-114

  Johnson, Elizabeth M ^a   Warnock, David W ^a   Luker, Jane ^b   Porter, Stephen R ^b   Scully, Crispian ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CD4 ANTIGEN; FLUCONAZOLE; KETOCONAZOLE; PYRROLE;

ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; CROSS RESISTANCE; DRUG RESISTANCE; FUNGUS CULTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUTH HYGIENE; THRUSH;

ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CANDIDIASIS, ORAL; DRUG RESISTANCE, MICROBIAL; FLUCONAZOLE; HIV INFECTIONS; HUMAN; KETOCONAZOLE; MICROBIAL SENSITIVITY TESTS; MOUTH; SUPPORT, NON-U.S. GOV'T;

EID: 0028927789     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/35.1.103     Document Type: Article

References (31)

1. Bart-Delabesse, E., Boiron, P., Carlotti, A., Dupont, B. (1993). Candida albicans genotyping in studies of patients with AIDS developing resistance to fluconazole. Journal of ClinicalMicrobiology 31, 2933-7.
2. Cameron, M. L., Schell, W. A., Bruch, S., Bartlett, J. A., Waskin, H. A., Perfect, J. R. (1993). Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy andsymptoms of individuals seropositive for human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy 37, 2449-53.
3. Dupxmy-Camet, J., Paugam, A., Di Donato, C., Viguie, C., Vicens, I., Voile, P. J. et al. (1991). Resistance au fluconazole en milieu hospitalier. Concordance entre la resistance de Candidaalbicans in vitro et l’echec thérapeutique. Presse Medicale 20, 1341.
4. Goodman, J. L., Winston, D. J., Greenfield, R. A., Chandrasekar, P. H., Fox, B., Kaizer, H. et al. (1992). A controlled trial of fluconazole to prevent fungal infections in patients undergoingbone marrow transplantation. New England Journal of Medicine 326, 845-51.
5. Hitchcock, C. A., Barrett-Bee, K. J., Russell, N. J. (1986). The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans. Journal of General Microbiology 132, 2421-31.
6. Hitchcock, C. A., Barrett-Bee, K. J., Russell, N. J. (1987). The lipid composition and permeability to azole of an azole- and polyene-resistant mutant of Candida albicans. Journalof Medical and Veterinary Mycology 25, 29-37.
7. Hitchcock, C. A., Pye, G. W., Troke, P. F., Johnson, E. M., Warnock, D. W. (1993). Fluconazole resistance in Candida glabrata. Antimicrobial Agents and Chemotherapy 37, 1962-5.
8. Horsburgh, C. R., Kirkpatrick, C. H. (1983). Long-term therapy of chronic mucocutaneous candidiasis with kétoconazole: experience with twenty-one patients. American Journal ofMedicine 74, Suppl. IB, 23-9.
9. Hughes, C. E., Bennett, R. L., Tuna, I. C., Beggs, W. H. (1988). Activities of fluconazole (UK 49, 858) and kétoconazole against ketoconazole-susceptible and-resistant Candida albicans.Antimicrobial Agents and Chemotherapy 32, 209-12.
10. Johnson, E. M. (1986). In Vitro Effects of Antifungal Drugs on Candida albicans and Phagocytic Cell Function., Ph.D. Thesis University of Bristol.
11. Johnson, E. M., Richardson, M. D., Warnock, D. W. (1984). In-vitro resistance to imidazole antifungals in Candida albicans. Journal of Antimicrobial Chemotherapy 13, 547-58.
12. Kitchen, V. S., Savage, M., Harris, J. R.W. (1991). Candida albicans resistance in AIDS. Journal of Infection 22, 204-5.
13. Marriott, M. S., Richardson, K. (1987). The discovery and mode of action of fluconazole. In Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents (Fromtling, R. A., Ed.), pp. 81-92. J. R. Prous Science Publishers, Barcelona.
14. National Committee for Clinical Laboratory Standards. (1992). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast. Proposed Standard M27-P. NCCLS, Villanova, PA.
15. Odds, F.C. (1985). Laboratory tests for the activity of imidazole and triazole antifungal agents in vitro. Seminars in Dermatology 4, 260-70.
16. Odds, F. C. (1993). Resistance of yeasts to azole-derivative antifungals. Journal of Antimicrobial Chemotherapy 31, 463-71.
17. Pfaller, M. A., Rhine-Chalberg, J., Redding, S. W., Smith, J., Farinacci, G., Fothergill, A. W. et al. (1994). Variations in fluconazole susceptibility and electrophoretic karyotype amongoral isolates of Candida albicans from patients with AIDS and oral candidosis. Journal ofClinical Microbiology 32, 59-64.
18. Plempel, M., Berg, D., Buchel, K.-H., Ritter, W. (1988). Experimental antimycotic activity of azole derivatives-experience, knowledge and questions. In Sterol Biosynthesis Inhibitors:Pharmaceutical and Agrochemical Aspects (Berg, D., Plempel, M., Eds), pp. 349-96. EllisHorwood, Chichester.
19. Rogers, T. E., Galgiani, J. N. (1986). Activity of fluconazole (UK 49, 858) and kétoconazole against Candida albicans in vitro and in vivo. Antimicrobial Agents and Chemotherapy 30, 418-22.
20. Rosenblatt, H. M., Byrne, W., Ament, M. E., Graybill, J., Stiehm, E. R. (1980). Successful treatment of chronic mucocutaneous candidiasis with kétoconazole. Journal of Pediatrics 97, 657-60.
21. Ryley, J. F., Wilson, R. G., Barrett-Bee, K. J. (1984). Azole resistance in Candida albicans. Sabouraudia 22, 53-63.
22. Smith, K. J., Wamock, D. W., Kennedy, C. T. C, Johnsoq, E. M., Hopwood, V., Van Cutsem, J. et al. (1986). Azole resistance in Candida albicans. Journal of Medical and VeterinaryMycology 24, 133-44.
23. Tavitian, A., Raufman, J. P., Rosenthal, L. E., Weber, J., Webber, C. A., Dincsoy, H. P. (1986). Ketoconazole-resistant Candida esophagitis in patients with acquired immunodeficiencysyndrome. Gastroenterology 90, 443-5.
24. Torssander, J., Morfeldt-Manson, L., Biberfield, G., Karlsson, A., Putkonen, P.-O., Wasser-man, J. (1987). Oral Candida albicans in HIV infection. Scandinavian Journal of Infectious Diseases 19, 291-5.
25. Vanden Bossche, H. (1985). Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. In Current Topics in Medical Mycology, Vol. 1 (McGinnis, M. R., Ed.), pp. 313-51. Springer-Verlag, New York.
26. Vanden Bossche, H., Marischal, P., Gorrens, J., Bellens, D., Moereels, H., Janssen, P. A. (1990). Mutation in cytochrome P-450-dependent 14 alpha-demethylase results in decreased affinityfor azole antifungals. Biochemical Society Transactions 18, 56-9.
27. Vanden Bossche, H., Marischal, P., Odds, F. C., Le Jeune, L., Coone, M.-C. (1992). Characterization of an azole-resistant Candida glabrata isolate. Antimicrobial Agents andChemotherapy 36, 2602-10.
28. Wamock, D. W., Johnson, E. M., Richardson, M. D., Vickers, C. F. H. (1983). Modified response to kétoconazole of Candida albicans from a treatment failure. Lancet ii, 642-3.
29. Willocks, L., Leen, C. L. S., Brettle, R. P., Urquhart, D., Russell, T. B., Milne, L. J. R. (1991). Fluconazole resistance in AIDS patients. Journal of Antimicrobial Chemotherapy 28, 937-9.
30. Wingard, J. R., Merz, W. G., Rinaldi, M. G., Johnson, T. R., Karp, J. E., Saral, R. (1991). Increase in Candida krusei infection among patients with bone marrow transplantation andneutropenia treated prophylactically with fluconazole. New England Journal of Medicine 325, 1274-7.
31. Winston, D. J., Chandrasekar, P. H., Lazarus, H. M., Goodman, J. L., Silber, J. L., Horowitz, H. et al. (1993). Fluconazole prophylaxis of fungal infections in patients with acute leukemia.Annals of Internal Medicine 118, 495-503.